One2Treat, The Company
One2Treat is dedicated to transforming the way biopharmaceutical companies design, analyze and interpret randomized clinical trials, and how the overall medical value of a treatment may be communicated. Through its innovative software platform and patient-centered methodologies, One2Treat helps sponsors incorporate the patient’s voice into early trial design, endpoint selection, and treatment value assessment. By aligning clinical evidence generation with patients and clinicians’ needs, One2Treat supports more meaningful clinical trials, efficient decision making and enhanced regulatory discussions, leading to faster market access.
OUR VISION
Through its innovative solutions, One2Treat envisions a future where clinical decisions are driven by what truly matters to patients, enabling a more personalized, preference-aligned care.
OUR MISSION
One2Treat’s mission is to develop methods and advanced software that enable a holistic evaluation of treatment effects by integrating all key patient-relevant outcomes into a single comprehensive assessment of the Net Treatment Benefit.
OUR UNIQUE VALUE
PROPOSITION
One2Treat applies state-of-the-art computing to the large volumes of patient data collected in clinical trials and supportive real-world evidence. This allows us to undertake more clinically meaningful statistical analysis of treatment effects, incorporating all outcomes that matter to patients. As a result, our approach significantly reduces trial sample sizes and expedites innovative treatments time to market.
ADVISORY BOARD
MEMBERS
- Rob Nichols
- Marc Buyse
- Damien Tremolet